InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,048.42
(
-0.46%
)
US TECH 100
17,162.80
(
0.60%
)
Dow Jones
38,085.80
(
-0.98%
)
Brent Oil
88.30
(
0.16%
)
Bitcoin
64,452.86
(
-0.05%
)
Post# of 672
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

realfast95

Send PM Follow Ignore
Followers 59
Posts 18522
Boards Moderated 0
Alias Born 11/29/2006

realfast95

Re: finesand post# 397

Thursday, 11/16/2017 5:25:20 AM

Thursday, November 16, 2017 5:25:20 AM

Post# of 672
You would have to get the analyst report from Gabelli to know why they downgraded.

Could be they are concerned that SPRIX is coming off patent.
That $200,000 in revenue from OXAYDO is a disappointment.

The risk of Egalet-002 is that it's no different than the comparison drug. Just like what happened at DRRX.

Lots of negatives
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up